Heron Therapeutics (HRTX) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Heron Therapeutics (HRTX) over the last 5 years, with Q3 2025 value amounting to -$0.1.
- Heron Therapeutics' EPS (Weighted Average and Diluted) fell 23333.33% to -$0.1 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.09, marking a year-over-year increase of 4375.0%. This contributed to the annual value of -$0.09 for FY2024, which is 8851.26% up from last year.
- Per Heron Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.1 for Q3 2025, which was down 23333.33% from -$0.02 recorded in Q2 2025.
- Heron Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $0.03 for Q4 2024, and its period low was -$0.63 during Q1 2022.
- In the last 5 years, Heron Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.15 in 2023 and averaged -$0.24.
- In the last 5 years, Heron Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 15474.62% in 2024 and then tumbled by 23333.33% in 2025.
- Quarter analysis of 5 years shows Heron Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.53 in 2021, then skyrocketed by 75.47% to -$0.13 in 2022, then soared by 61.54% to -$0.05 in 2023, then skyrocketed by 154.75% to $0.03 in 2024, then crashed by 465.32% to -$0.1 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.1 for Q3 2025, versus -$0.02 for Q2 2025 and $0.01 for Q1 2025.